Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Pancreatic Cancer
What systemic therapy regimen would you use for MSI-High resectable PDAC of the tail of the pancreas?
Related Questions
Would you offer surgery for an MSI-H pancreatic adenocarcinoma who had deep response to pembrolizumab?
What are your top takeaways from ASCO GI 2025?
How do you approach patients with partially occlusive thrombus in the splenic vein posterior to the pancreatic cancer lesion?
What systemic therapy and dose adjustments would you implement for patients with pancreas cancer and cirrhosis with pancytopenia?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
When a patient with pancreatic cancer received neoadjuvant chemo + chemo-RT, how do you manage an in-field, post operative positive margin?
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
Would you consider using enasidenib off-label for a cholangiocarcinoma with IDH2 mutation that has progressed on numerous lines of standard of therapy?
